| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1531-8249(200101)49:1<29::AID-ANA7>3.3.CO;2-2 |
| P698 | PubMed publication ID | 11198293 |
| P50 | author | L. Adrienne Cupples | Q37638868 |
| Richard H Myers | Q42418674 | ||
| Edward D. Bird | Q84176647 | ||
| Estrella Gómez-Tortosa | Q101136972 | ||
| James F. Gusella | Q1602688 | ||
| P2093 | author name string | Taylor SA | |
| MacDonald ME | |||
| Vonsattel JP | |||
| Friend JC | |||
| Srinidhi J | |||
| Weiler LJ | |||
| P433 | issue | 1 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 29-34 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Quantitative neuropathological changes in presymptomatic Huntington's disease | |
| P478 | volume | 49 |
| Q34386162 | Abnormal motor cortex excitability in preclinical and very early Huntington's disease |
| Q36838442 | Alterations in brain transition metals in Huntington disease: an evolving and intricate story |
| Q59130166 | Altered Intracortical T-Weighted/T-Weighted Ratio Signal in Huntington's Disease |
| Q93390942 | Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI |
| Q41765226 | Biomarkers to predict and track diseases |
| Q33619310 | Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? |
| Q33861321 | Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study |
| Q42755788 | Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington's disease |
| Q34394979 | Deep white matter in Huntington's disease |
| Q33671108 | Developmental Whole Brain White Matter Alterations in Transgenic Huntington's Disease Monkey |
| Q35253106 | Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease |
| Q36011977 | Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. |
| Q30437914 | Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice |
| Q48293707 | Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes |
| Q27023050 | Genetics and neuropathology of Huntington's disease |
| Q33760994 | Huntington disease models and human neuropathology: similarities and differences |
| Q36456618 | Huntington's Disease as Neurodevelopmental Disorder: Altered Chromatin Regulation, Coding, and Non-Coding RNA Transcription. |
| Q30426968 | Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. |
| Q38884155 | Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity |
| Q34709693 | Is a motor criterion essential for the diagnosis of clinical huntington disease? |
| Q40644113 | Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. |
| Q41563536 | Metabolic and transcriptomic analysis of Huntington's disease model reveal changes in intracellular glucose levels and related genes |
| Q49186119 | MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study |
| Q41490462 | Microstructural brain abnormalities in Huntington's disease: A two-year follow-up |
| Q34624765 | Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study |
| Q30481208 | Mouse models of Huntington's disease and methodological considerations for therapeutic trials |
| Q30670030 | Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study. |
| Q45305061 | Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications |
| Q37131243 | Neuroprotection for Huntington's disease: ready, set, slow |
| Q38096248 | Oligodendroglia and neurotrophic factors in neurodegeneration |
| Q27001671 | PGC-1α, mitochondrial dysfunction, and Huntington's disease |
| Q35821216 | Parallel basal ganglia circuits for voluntary and automatic behaviour to reach rewards |
| Q42792348 | Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease |
| Q45297446 | Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease. |
| Q35487438 | Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. |
| Q45306451 | Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. |
| Q34514619 | Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment |
| Q33941486 | Striatal and white matter predictors of estimated diagnosis for Huntington disease |
| Q36934002 | Striatal oligodendrogliogenesis and neuroblast recruitment are increased in the R6/2 mouse model of Huntington's disease |
| Q36025447 | Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model |
| Q37530250 | Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease |
| Q36070777 | Systems Genetic Analyses Highlight a TGFβ-FOXO3 Dependent Striatal Astrocyte Network Conserved across Species and Associated with Stress, Sleep, and Huntington's Disease |
| Q45301247 | The role of iron in gray matter degeneration in Huntington's disease: a magnetic resonance imaging study. |
| Q35147342 | miR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement |
Search more.